CAM
GALT icon

Cormorant Asset Management’s Galectin Therapeutics GALT Stock Holding History

Cormorant Asset Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-286,200
Closed -$670K – 86
2015
Q3 		$670K Hold
286,200
– – 0.11% 79
2015
Q2 		$781K Hold
286,200
– – 0.1% 74
2015
Q1 		$959K Sell
286,200
-25,800
-8% -$92.2K 0.15% 63
2014
Q4 		$1.08M Sell
312,000
-138,400
-31% -$612K 0.17% 60
2014
Q3 		$2.27M Sell
450,400
-349,600
-44% -$2.72M 0.47% 46
2014
Q2 		$11M Buy
800,000
+452,000
+130% +$5.63M 2.93% 12
2014
Q1 		$5.33M Buy
+348,000
New +$4.96M 1.23% 29

Other funds holding GALT

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
BCCM
Blue Clay Capital Management Minneapolis, Minnesota $88.7M AUM 6.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Cormorant Asset Management's GALT Position: Q4 2015 in Review

Cormorant Asset Management sold out of Galectin Therapeutics (GALT) in Q4 2015, closing a stake of 286,200 shares — an estimated $670K sold.

Cormorant Asset Management first reported a position in GALT in Q1 2014 and held it in 7 quarters. The position peaked at $11M in Q2 2014. 58 funds tracked by Wall St. Rank hold GALT as of Q4 2015.

  • Cormorant Asset Management reported no remaining Galectin Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Cormorant Asset Management sold 286,200 Galectin Therapeutics shares in Q4 2015, an estimated $670K.
  • Cormorant Asset Management first reported a position in Galectin Therapeutics in Q1 2014 and held it in 7 quarters.
  • Cormorant Asset Management's Galectin Therapeutics position peaked at $11M in Q2 2014.
  • 58 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2015.

Based on Cormorant Asset Management's 13F filing for Q4 2015, filed 16 Feb 2016.